A polymer with a hemocompatible film or coating is manufactured by a one-step method comprising polymerizing monomer droplets comprising at least one crosslinking agent to form a polymer and simultaneously coating the resulting polymer using at least one dispersing agent to thereby form a hemocompatible coated polymer.
|
1. A method of manufacturing a biocompatible coat polymer, said method comprising:
polymerizing monomer droplets comprising at least one cross agent to form a polymer and simultaneously coating said resultant polymer using a least one polymeric dispersing agent to thereby form a biocompatible coated polymer.
2. The method of
7. The method of
8. The method of
9. The method of
10. The method of
11. The method of
13. The method of
|
|||||||||||||||||||||||||||
1. Field of the Invention
The present invention relates to a polymer with a hemocompatible coating comprising at least one crosslinking agent for making the polymer and at least one dispersing agent whereby the dispersing agent forms a hemocompatible surface coating on the polymer. More specifically, the present invention relates to a hemocompatible coated polymer manufactured by a method comprising simultaneously polymerizing and coating with at least one crosslinking agent for making the polymer and using at least one dispersing agent to form a hemocompatible coated polymer.
2. Description of Related Art
It has been known and practiced in the art of suspension polymerization to manufacture polymers with a hemocompatible coating using a two-step process. In the first step of the two-step process, polymeric beads are manufactured by polymerizing monomer droplets using suspension polymerization. In the second step of the process, a hemocompatibilizing film is applied onto the exterior surface of the polymer to provide the hemocompatible coating. Unlike the prior art, the polymers of the present invention are manufactured using a one step process which utilizes at least one dispersing agent to form a hemocompatible surface coating on the polymer.
The present invention relates to a polymer with a hemocompatible coating comprising at least one crosslinking agent for making the polymer and at least one dispersing agent whereby the dispersing agent forms a hemocompatible surface on the polymer. In one embodiment, the dispersing agent comprises a biocompatibilizing polymer.
In another embodiment, the biocompatibilizing polymer comprises poly(N-vinylpyrrolidinone). In still another embodiment, the biocompatibilizing polymer is selected from a group consisting of poly(hydroxyethyl methacrylate), poly(hydroxyethyl acrylate), poly(dimethylaminoethyl methacrylate), salts of poly(acrylic acid), salts of poly(methacrylic acid), poly(diethylaminoethyl methacrylate), poly(hydroxypropyl methacrylate), poly(hydroxypropyl acrylate), poly(N-vinylpyrrolidinone), poly(vinyl alcohol) and mixtures thereof. In another embodiment, the salts may be sodium and potassium salts and in still another embodiment, the salts are water-soluble salts.
In yet another embodiment, the dispersing agent is selected from a group consisting of hydroxyethyl cellulose, hydroxypopyl cellulose, poly(hydroxyethyl methacrylate), poly(hydroxyethyl acrylate), poly(hydroxypropyl methacrylate), poly(hydroxypropyl acrylate), poly(dimethylaminoethyl methacrylate), poly(dimethylaminoethyl acrylate), poly(diethylaminoethyl methacrylate), poly(diethylaminoethyl acrylate), poly(vinyl alcohol), salts of poly(methacrylic acid), and salts of poly(acrylic acid) and mixtures thereof.
In still another embodiment, the crosslinking agent is selected from a group consisting of divinylbenzene, trivinylbenzene, divinylnaphthalene, trivinylcyclohexane, divinylsulfone, trimethylolpropane trimethacrylate, trimethylolpropane dimethacrylate, trimethylolpropane triacrylate, trimethylolpropane diacrylate, pentaerythrital tetra-, tri-, and dimethacrylates, pentaerythritol tetra-, tri- and diacrylates, dipentaerythritol tetra, tri-, and dimethacrylates, dipentaerythritol tetra-, tri-, and diacrylates, divinylformamide, and mixtures thereof.
In still yet another embodiment, the crosslinking agent comprises divinylbenzene. In a further embodiment, the crosslinking agent comprises trivinylcylohexane. In yet a further embodiment, the crosslinking agent comprises trivinylbenzene.
In still a further embodiment, the crosslinking agent comprises copolymers of divinylbenzene with comonomers being selected from a group consisting of styrene, ethylstyrene, acrylonitrile, butyl methacrylate, octyl methacrylate, butyl acrylate, octyl acrylate, cetyl methacrylate, cetyl acrylate, ethyl methacrylate, ethyl acrylate, vinyltoluene, vinylnaphthalene, vinylbenzyl alcohol, vinylformamide, methyl methacrylate, methyl acrylate and mixtures thereof.
In still yet a further embodiment, the polymer with the hemocompatible surface is a porous polymer. In another further embodiment, the polymer with the hemocompatible surface is an ion exchange polymer. In a further embodiment, the polymer is an affinity polymer. In yet another further embodiment, the biocompatibilizing polymer becomes grafted to the surface of the polymer to provide a polymer with the hemocompatible surface. For purposes of this invention, the term “grafting” is defined as chemically bonded with potential entanglement such that the dispersing agent is physically restricted from leaving the surface of the polymer.
In another embodiment, the present invention relates to a polymer manufactured by a process comprising: simultaneously polymerizing and coating with at least one crosslinking agent for making the polymer and using at least one dispersing agent to form a hemocompatible coated polymer.
For purposes of this invention, the term “hemocompatibility” is defined as a condition whereby a material, when placed in contact with whole blood and blood components or physiological fluids, results in clinically acceptable physiological changes. In another embodiment, the dispersing agent is a biocompatibilizing polymer. A “biocompatibilizing polymer” is defined as a polymer, which forms a surface over a non-biocompatible material, making the polymeric system compatible with physiological fluids and tissues. The term “crosslinking agent” is defined as a linking agent such as a polyfunctional monomer that links two or more polymer chains or segments of the same polymer chain together. The term “dispersing agent” is defined as a substance that imparts a stabilizing effect upon a finely divided array of immiscible particles suspended in a fluidizing medium. The immiscible particles can be a solid, liquid or gas and the fluidizing medium can be a liquid or a gas.
In another embodiment, the crosslinking agent is polymerized with at least one vinyl monomer. In a further embodiment, the dispersing agent forms a hemocompatible coating on a surface of the polymer. In yet a further embodiment, the coating of the polymer is equivalent to the surface of the polymer.
In another embodiment, the dispersing agent comprises a biocompatibilizing polymer. In still another embodiment, the biocompatibilizing polymer is poly(N-vinylpyrrolidinone). In another embodiment, the biocompatibilizing polymer is poly(vinyl alcohol). In yet another embodiment, the biocompatibilizing polymer is selected from a group consisting of poly(hydroxyethyl methacrylate), poly(hydroxyethyl acrylate), poly(dimethylaminoethyl methacrylate), salts of poly(acrylic acid), salts of poly(methacrylic acid), poly(diethylaminoethyl methacrylate), poly(hydroxypropyl methacrylate), poly(hydroxypropyl acrylate), poly(N-vinylpyrrolidinone), poly(vinyl alcohol) and mixtures thereof. For purposes of this invention, any biocompatibilizing polymer that can function as a dispersant can be used in accordance with this invention.
In a further embodiment, the dispersing agent is selected from a group consisting of hydroxyethyl cellulose, hydroxypopyl cellulose, poly(hydroxyethyl methacrylate), poly(hydroxyethyl acrylate), poly(hydroxypropyl methacrylate), poly(hydroxypropyl acrylate), poly(dimethylaminoethyl methacrylate), poly(dimethylaminoethyl acrylate), poly(diethylaminoethyl methacrylate), poly(diethylaminoethyl acrylate), poly(vinyl alcohol), salts of poly (methacrylic acid), and salts of poly(acrylic acid) and mixtures thereof.
In still a further embodiment, the crosslinking agent is selected from a group consisting of divinylbenzene, trivinylbenzene, divinylnaphthalene, trivinylcyclohexane, divinylsulfone, trimethylolpropane trimethacrylate, trimethylolpropane dimethacrylate, trimethylolpropane triacrylate, trimethylolpropane diacrylate, pentaerythrital tetra-, tri-, and dimethacrylates, pentaerythritol tetra-, tri- and diacrylates, dipentaerythritol tetra, tri-, and dimethacrylates, dipentaerythritol tetra-, tri-, and diacrylates, divinylformamide and mixtures thereof. In yet a further embodiment, the crosslinking agent comprises divinylbenzene. In still a further embodiment, the crosslinking agent comprises trivinylbenzene. In still another further embodiment, the crosslinking agent comprises divinylnaphthalene. In yet another further embodiment, the crosslinking agent comprises trivinylcylohexane.
In still yet a further embodiment, the crosslinking agent comprises copolymers of divinylbenzene with comonomers selected from a group consisting of styrene, ethylstyrene, acrylonitrile, butyl methacrylate, octyl methacrylate, butyl acrylate, octyl acrylate, cetyl methacrylate, cetyl acrylate, ethyl methacrylate, ethyl acrylate, vinyltoluene, vinylnaphthalene, vinylbenzyl alcohol, vinylformamide and mixtures thereof.
In still a further embodiment, the polymer is processed in non-pyrogenic water. For purposes of this invention, “non-pyrogenic” shall be defined by U.S.P. 25, Monograph (151) Pyrogenic Test, U.S. Pharmacopeia National Formulary.
In still yet another embodiment, the polymer of the present invention is prepared by suspension polymerization. For purposes of the invention, suspension polymerization is defined as the polymerization of monomer droplets dispersed in an immiscible liquid. Based upon an Elemental Analysis of the Polymer's Surface by X-Ray Photoelectron Spectroscopy (XPS), the dispersing agent becomes chemically grafting onto the surface of the polymer as the monomer droplets are transformed into polymeric beads. Polymers coated with poly(N-vinylpyrrolidinone) have been found to be biocompatible and hemocompatible. The hemocompatible polymers of the present invention pass the Lee White clotting tests and the tests for the hemolysis of red blood cells.
In another embodiment, the polymer of the present invention is a porous polymer. The term “porous polymer” is defined as a polymer particle having an internal pore structure with a porosity resulting from voids or holes throughout the polymer matrix. In still another embodiment, the polymer is an ion exchange resin or polymer. An ion exchange resin or polymer is a resin or polymer carrying ionogenic groups that are capable of exchanging ions or of sequestering ions. The ion exchange polymers of the present invention are beneficial when used with blood for removing and isolating varying ions and ionogenic molecules.
In still yet another embodiment, the present invention relates to a polymer with a hemocompatibilizing surface coating. In a further embodiment, the coated polymer is manufactured by a one step process comprising: simultaneously coating and polymerizing monomer droplets in a suspension polymerization procedure with at least one dispersing agent having encapsulated the droplets with a hemocompatible coating to thereby form a polymer with a hemocompatible surface-coating grafted onto the surface of the polymer beads.
In another further embodiment, the dispersing agent comprises a biocompatibilizing polymer. In still a further embodiment, the biocompatibilizing polymer is poly(N-vinylpyrrolidinone). In yet a further embodiment, the biocompatibilizing polymer is selected from a group consisting of poly(hydroxyethyl methacrylate), poly(hydroxyethyl acrylate), poly(dimethylaminoethyl methacrylate), salts of poly(acrylic acid), salts of poly(methacrylic acid), poly(diethylaminoethyl methacrylate), poly(hydroxypropyl methacrylate), poly(hydroxypropyl acrylate), poly(N-vinylpyrrolidinone), poly(vinyl alcohol) and mixtures thereof. In still yet a further embodiment, the polymer geometry comprises beads, spheroids, pellets, granules and mixtures thereof.
In a further embodiment, the monomer droplets are selected from a group consisting of divinylbenzene, styrene, ethylstyrene, acrylonitrile, butyl acrylate, butyl methacrylate, vinyltoluene, vinylnaphthalene, octyl methacrylate, octyl acrylate, cetyl methacrylate, cetyl acrylate, ethyl methacrylate, ethyl acrylate, vinylbenzyl alcohol, vinylformamide and mixtures thereof.
In another embodiment, the present invention relates to a method of manufacturing a biocompatible and hemocompatible surface coated polymer. In still another embodiment, the method comprises: polymerizing monomer droplets comprising at least one crosslinking agent and simultaneously coating the resulting polymer beads using at least one dispersing agent to form a biocompatible surface coated polymer. In still another embodiment, the coated polymers are hemocompatible. In yet another embodiment, the polymer is formed using a suspension polymerization procedure. In another embodiment, the polymer is formed using an emulsion polymerization procedure followed by growing the particles with additional monomer feed.
In still another embodiment, the present invention relates to an application of use whereby the hemocompatible surface coated polymers of the present invention are utilized for medical applications. In another embodiment, the hemocompatible polymers of the present invention may be used to isolate and/or remove target substances from blood and physiological fluids and for specific treatments. In a further embodiment, the hemocompatible polymers of the present invention may be used in preserving organs. In yet another embodiment, the present invention relates to an apparatus for isolating blood components and for purifying blood using the hemocompatible surface coated polymers of the present invention. In one embodiment, the apparatus comprises a cartridge containing the hemocompatible polymers of the present invention.
In yet a further embodiment, the present invention relates to a polymer with a hemocompatible surface coating, the polymer being manufactured by a method comprising: polymerizing monomer droplets comprising at least one crosslinking agent to form a polymer and developing a surface coating on the polymer by using at least one dispersing agent carrying hydroxyl groups followed by a reaction of hydroxyl groups with a vinyl monomer or polymer to thereby form the hemocompatible surface coating on the polymer.
In still yet a further embodiment, the present invention also relates to a method of manufacturing a hemocompatible surface coated polymer using a one step process, the method comprising: polymerizing monomer droplets comprising at least one crosslinking agent to form a polymer and developing a surface coating on the polymer by using at least one dispersing agent carrying hydroxyl groups followed by a reaction of hydroxyl groups with a vinyl monomer or polymer to thereby form the hemocompatible surface coating on the polymer.
In another embodiment, the present invention relates to a polymer having a hemocompatible-coated surface, the polymer being manufactured by a two-step process comprising: polymerizing monomer droplets comprising at least one crosslinking agent and at least one dispersing agent to form a polymer; and coating the surface of the polymer by crosslinking a monovinyl monomer and a polyfunctional monomer mixture over the surface of the polymer bead to thereby form the hemocompatible coating on the surface of the polymer.
In a further embodiment, the present invention relates to a method comprising: polymerizing monomer droplets comprising at least one crosslinking agent and at least one dispersing agent to form a polymer; and coating the surface of the polymer by crosslinking a monovinyl monomer and a polyfunctional monomer mixture over the surface of the polymer bead to thereby form the hemocompatible coating on the surface of the polymer.
In another embodiment, the present invention relates to a hemocompatible system comprising an organic phase and an aqueous phase, wherein the organic phase composed of the polymerizable monomers and the porogen are dispersed into a slurry of droplets by agitation throughout the aqueous phase which is formulated to effect the stability of the droplets by the water-miscible dispersant and to quench polymer growth in the aqueous phase by carrying a water-soluble free radical inhibitor.
As required, detailed embodiments of the present invention are disclosed herein; however, it is to be understood that the disclosed embodiments are merely exemplary of the invention that may be embodied in various forms. The figures are not necessary to scale, some features may be exaggerated to show details of particular components. Therefore, specific structural and functional details disclosed herein are not to be interpreted as limiting, but merely as a basis for the claims and as a representative basis for teaching one skilled in the art to variously employ the present invention.
The specific example below will enable the invention to be better understood. However, they are given merely by way of guidance and do not imply any limitation.
The first polymer synthesis was targeted at an aqueous to organic volume ratio of 1.0. Table 1 below illustrates the targeted dispersion mixture designed for Example 1 using a fifty (50) liter reaction.
| TABLE 1 | |
| Dispersion Mixture Desires for 50 Liters | |
| Aqueous/Organic Volume Ratio | 1.0 |
| Volume of Organic Phase, ml | 25,000.0 |
| Volume of Aqueous Phase, ml | 25,000.0 |
| Density of Organic Phase, g/ml | 0.83490 |
| Weight of Organic Phase, g | 20,872.5 |
| Density of Aqueous Phase, g/ml | 1.005 |
| Weight of Aqueous Phase, g | 25,125.0 |
| Polymerizable Monomers, DVB plus EVB, g | 8766.45 |
| Total Volume of Organic & Aqueous Phases, ml | 50,000.0 |
| Total Weight of Organic & Aqueous Phases, g | 45,997.5 |
The procedure for the polymerization in Example 1 is initiated by the preparation of an aqueous phase and an organic phase. Table 2 and 3 below illustrate the components of the aqueous phase composition for the polymer synthesis by weight percent (%) and by quantity of the components in grams (g), respectively.
| TABLE 2 | ||
| Aqueous Phase Composition | ||
| Ultrapure Water, wt. % | 98.089 | |
| Water from Aqueous 45% Solution of | 0.611 | |
| Poly (N-vinylpyrrolidinone), wt. % | ||
| Poly(N-vinylpyrrolidinone) Pure, wt. % | 0.500 | |
| Sodium Carbonate, wt. % | 0.500 | |
| Sodium Nitrite, wt. % | 0.300 | |
Other dispersants, such as poly(vinyl alcohol) have been used as a substitute for the poly(N-vinylpyrrolidinone).
| TABLE 3 | |
| Aqueous Phase Charges | |
| Ultrapure Water, g | 24,644.83 |
| Water from Aqueous 45% Solution of | (153.542) |
| Poly(N-vinylpyrrolidinone), g | |
| Poly(N-vinylpyrrolidinone) Pure, g | (125.625) |
| Aqueous Poly(N-vinylpyrrolidinone) Solution, | 279.167 |
| 45 wt. %, g | |
| Sodium Carbonate, g | 125.625 |
| Sodium Nitrite, g | 75.375 |
| Weights in parenthesis are part of other charged materials | |
| Total Weight of Aqueous Phase, g | 25,124.997 |
Table 4 and 5 illustrate the components of the organic phase composition for the polymer synthesis by weight percent (5) and by quantity of the components in grams (g), respectively.
| TABLE 4 | ||
| Organic Phase Composition | ||
| Divinylbenzene (DVB), wt. % | 26.998 | |
| Ethylvinylbenzene (EVB), wt. % | 15.0024 | |
| Inerts, wt. % | 0.41567 | |
| Toluene, wt. % | 27.134 | |
| Isooctane, wt. % | 30.450 | |
| Benzoyl Peroxide, wt. % of polymerizable monomers | 1.03 | |
Other immiscible porogens such as isooctane, cyclohexane and nonane have been substituted, both singularly and in combination with one another, for the mixture of toluene and isooctane.
| TABLE 5 | ||
| Organic Phase Charges | ||
| Divinylbenzene, Pure, g | (5635.069) | |
| Ethylvinylbenzene, Pure, g | (3131.381) | |
| Commercial DVB, Dow 63.5%, g | 8853.211 | |
| Inerts, g | (86.761) | |
| Toluene, g | 5663.613 | |
| Isooctane, g | 6355.676 | |
| Weights in parenthesis are part of commercial DVB | ||
| Total Weight of Organic Phase, g (excluding BPO) | 20,872.50 | |
| Benzoyl Peroxide, BPO, Pure, g | 90.294 | |
| 75 weight percent BPO, g | 120.393 | |
| 97 weight oercent BPO, g | 93.087 | |
Upon preparation of the aqueous and organic phases, the aqueous phase is introduced into the reactor. The reactor is set at an agitation rate of approximately 86 revolutions per minute. The aqueous phase is then heated to 65 degrees Celsius with agitation and a nitrogen sweep through the headspace in order to displace oxygen from the reactor space. The organic phase is then introduced into the reactor by pouring or pumping the organic phase onto the aqueous phase under agitation at a stirring rate of at least 86 revolutions per minute. The droplet dispersion is then stirred at 86 revolutions per minute for at least fifteen (15) minutes to set the droplet size and allow the droplet slurry to equilibrate as the temperature is raised from about 65 degrees to about 70 degrees Celsius. Once the droplet dispersion is homogenous throughout the reaction volume, the slurry is then heated to about 75 plus or minus 2.0 degrees Celsius and held at that temperature for ten (10) hours.
The slurry is cooled to about 70 degrees Celsius and the stirrer is turned off, and the polymer beads are allowed to collect at the top of the fluid bed. The mother liquor is then removed from the bottom of the reactor via a pump until the bead bed approaches within about one (1) inch from the bottom of the reactor. The mother liquor is discarded.
A sufficient amount of ultrapure water at ambient temperature is added to fluidize the bead bed. The quality of water needed to wash the beads will be approximately one (1) bed volume or about 25 liters of water. Upon adding the water, the stirrer is then restarted and agitated at a stir rate of 106 revolutions per minute for about five (5) minutes. The stirring is stopped and the beads are allowed to collect at the top of the fluid bed.
The liquor is then drained from the bottom of the reactor via a pump until the bead bed approaches within about one (1) inch from the bottom of the reactor. The wash liquor is discarded. The beads are then washed with the ultrapure water for at least five (5) washes or until the bulk fluid is transparent and free of junk polymer (a clear liquor is achieved). The water-wet bead slurry is transferred to a column that is fitted with a solid-liquid separator at the bottom of the column. The separator may be a mesh or screen made from Teflon, nylon, polypropylene, stainless steel, or glass with pore openings in the size from about 100 to about 300 microns.
The porogen mixture is displaced from the beads by a downflow treatment with ten (10) bed volumes of isopropyl alcohol at a flow rate of one (1) bed volume per hour. The isopropyl alcohol is displaced from the beads with water at a downflow treatment with ten (10) bed volumes of ultrapure water (pyrogen and endotoxin free) at a flow rate of one (1) bed volume per hour. The polymer beads are then transferred from the column into plastic containers for transport to the thermal steam-flux cleaner.
Experiments were performed using the polymer beads manufactured by the polymerization procedures described in Example 1 and the measured results on the polymer products are illustrated in Tables 6-7 set forth below:
| TABLE 6 | ||||||||||||
| Experimental Program: Input | ||||||||||||
| Sample | Sample | Sample | Sample | Sample | Sample | Sample | ||||||
| ID | Sample ID | ID | Sample ID | ID | ID | ID | ID | ID | Sample ID | Sample ID | ||
| LDM | 02-001 | 02-004 | 02-006 | 02-008 | 02-010 | 02-012 | 02-015 | 02-016 | 02-017 | 02-022 | 02-025 | |
| Organic Phase | ||||||||||||
| Composition | ||||||||||||
| Monomer (DVB & EVB) Wt. % | 42.0 | 42.0 | 42.0 | 42.0 | 40.7 | 50.0 | 40.0 | 40.0 | 45.0 | 45.0 | 45.0 | |
| Porogen Wt. % | 58.0 | 58.0 | 58.0 | 58.0 | 59.3 | 50.0 | 60.0 | 60.0 | 55.0 | 55.0 | 55.0 | |
| Porogen/Monomer Ratio | 1.3810 | 1.3810 | 1.3810 | 1.3810 | 1.457 | 1.000 | 1.500 | 1.500 | 1.222 | 1.222 | 1.222 | |
| Benzoyl Peroxide (BPO) | 1.03 | 1.03 | 1.03 | 1.03 | 1.03 | 1.03 | 1.03 | 1.03 | 1.03 | 1.03 | 1.03 | |
| Wt. % | ||||||||||||
| Porogen Composition | ||||||||||||
| Isooctane, Wt. % | 52.5 | 52.5 | 52.5 | 52.5 | 53.5 | 60.0 | 99.327 | 99.327 | 99.174 | 99.174 | 99.174 | |
| Toluene, Wt. % | 46.769 | 46.769 | 46.769 | 46.769 | 45.81 | 38.99 | 0 | 0 | 0 | 0 | 0 | |
| Inerts, Wt. % | 0.731 | 0.731 | 0.731 | 0.731 | 0.693 | 1.010 | 0.6734 | 0.826 | 0.826 | 0.826 | 0.726 | |
| Toluene plus Inerts, Wt. % | 47.5 | 47.5 | 47.5 | 47.5 | 46.5 | 40.0 | — | — | — | — | — | |
| Isooctane/Toluene plus Inerts | 1.105 | 1.105 | 1.105 | 1.105 | 1.1505 | 1.500 | — | — | — | — | — | |
| Ratio | ||||||||||||
| Aquoeus Phase | ||||||||||||
| Composition | ||||||||||||
| Sodium Carbonate, Wt. % | 0.500 | 0.500 | 0.500 | 0.500 | 0.500 | 0.500 | 0.500 | 0.500 | 0.500 | 0.500 | 0.500 | |
| Sodium Nitrate, Wt. % | 0.300 | 0.300 | 0.300 | 0.300 | 0.300 | 0.300 | 0.300 | 0.300 | 0.300 | 0.300 | 0.300 | |
| Poly(N-Vinylpyrrolidione) Wt. % | 0.500 | 0.500 | 0.450 | 0.400 | 0.400 | 0.400 | 0.100 | 0.400 | 0.500 | 0.500 | 1.000 | |
| PVP K 30, 45-55 Kdaltons, | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.250 | 1.000 | |
| Wt. % | ||||||||||||
| PVP K 60, 400-500 Kdaltons, | 0.500 | 0.500 | 0.450 | 0.400 | 0.400 | 0.400 | 0.100 | 0.400 | 0.500 | 0.250 | 0 | |
| Wt. % | ||||||||||||
| Poly(Vinyl alcohol), Wt. % | 0.01 | 0.01 | 0.05 | 0.100 | 0.100 | 0.100 | 0.400 | 0.100 | 0 | 0 | 0 | |
| Molecular Size, Kdaltons | 88.0 | 88.0 | 95.0 | 95.0 | 95.0 | 95.0 | 95.0 | 95.0 | — | — | — | |
| Amount Hydrolyzed, % | 85 | 85 | 95 | 95 | 95 | 95 | 95 | 95 | — | — | — | |
| Aqueous/Organic Phase | 0.9 | 0.9 | 0.9 | 0.9 | 0.9 | 0.9 | 0.9 | 0.9 | 0.9 | 1.1 | 1.1 | |
| Volume Ratio | ||||||||||||
| Sample | Sample | Sample | Sample | Sample | Sample | Sample | Sample | Sample | Sample | Sample | Sample | |
| ID | ID | ID | ID | ID | ID | ID | ID | ID | ID | ID | ID | |
| LDM | 02-028 | 02-029 | 02-030 | 02-031 | 02-032 | 02-033 | 02-034 | 02-036 | 02-038 | 02-040 | 02-042 | 02-044 |
| Organic Phase | ||||||||||||
| Composition | ||||||||||||
| Monomer (DVB & EVB) Wt. % | 45.0 | 45.0 | 45.0 | 45.0 | 45.0 | 50.0 | 55.0 | 55.0 | 55.0 | 55.0 | 55.0 | 55.0 |
| Porogen Wt. % | 55.0 | 55.0 | 55.0 | 55.0 | 55.0 | 50.0 | 45.0 | 45.0 | 45.0 | 45.0 | 45.0 | 45.0 |
| Porogen/Monomer Ratio | 1.222 | 1.222 | 1.222 | 1.222 | 1.222 | 1.000 | 0.8182 | 0.8182 | 0.8182 | 0.8182 | 0.8182 | 0.8182 |
| Benzoyl Peroxide (BPO) | 1.03 | 1.03 | 1.03 | 1.03 | 1.03 | 1.03 | 1.03 | 1.03 | 1.03 | 1.03 | 1.03 | 1.03 |
| Wt. % | ||||||||||||
| Porogen Composition | ||||||||||||
| Isooctane, Wt. % | 99.274 | 99.274 | 99.274 | 99.274 | 99.274 | 99.1122 | 98.915 | 98.915 | 98.915 | 98.915 | 98.915 | 98.915 |
| Toluene, Wt. % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inerts, Wt. % | 0.726 | 0.726 | 0.726 | 0.726 | 0.726 | 0.8878 | 1.085 | 1.085 | 1.085 | 1.085 | 1.085 | 1.085 |
| Toluene plus Inerts, Wt. % | — | — | — | — | — | — | — | — | — | — | — | — |
| Isooctane/Toluene plus Inerts | — | — | — | — | — | — | — | — | — | — | — | — |
| Ratio | ||||||||||||
| Aqueous Phase | ||||||||||||
| Composition | ||||||||||||
| Sodium Carbonate, Wt. % | 0.500 | 0.500 | 0.500 | 0.500 | 0.500 | 0.500 | 0.500 | 0.500 | 0.500 | 0.500 | 0.500 | 0.500 |
| Sodium Nitrate, Wt. % | 0.300 | 0.300 | 0.300 | 0.300 | 0.300 | 0.300 | 0.300 | 0.300 | 0.300 | 0.300 | 0.300 | 0.300 |
| Poly(N-Vinylpyrrolidione) Wt. % | 0.700 | 0.900 | 1.000 | 1.000 | 1.500 | 1.000 | 0.500 | 1.300 | 1.100 | 1.000 | 0.200 | 0.300 |
| PVP K 30, 45-55 Kdaltons, | 0.700 | 0.900 | 1.000 | 1.000 | 1.500 | 0.900 | 0 | 1.000 | 1.000 | 0.800 | 0 | 0 |
| Wt. % | ||||||||||||
| PVP K 60, 400-500 Kdaltons, | 0 | 0 | 0 | 0 | 0 | 0.100 | 0.500 | 0.300 | 0.100 | 0.200 | 0.200 | 0.300 |
| Wt. % | ||||||||||||
| Poly(Vinyl alcohol), Wt. % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Molecular Size, Kdaltons | — | — | — | — | — | — | — | — | — | — | — | — |
| Amount Hydrolyzed, % | — | — | — | — | — | — | — | — | — | — | — | — |
| Aqueous/Organic Phase | 1.2 | 1.2 | 1.145 | 1.2 | 1.2 | 1.1 | 1.1 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 |
| Volume Ratio | ||||||||||||
| Sample | Sample | Sample | Sample | Sample | Sample | Sample | Sample | Sample | Sample | Sample | Sample | |
| ID | ID | ID | ID | ID | ID | ID | ID | ID | ID | ID | ID | |
| LDM | 02-047 | 02-049 | 02-050 | 02-052 | 02-054 | 02-055 | 02-059 | 02-061 | 02-073 | 02-074 | 02-075 | 02-079 |
| Organic Phase | ||||||||||||
| Composition | ||||||||||||
| Monomer (DVB & EVB) Wt. % | 55.0 | 55.0 | 55.0 | 55.0 | 55.0 | 55.0 | 55.0 | 55.0 | 55.0 | 55.0 | 55.0 | 55.0 |
| Porogen Wt. % | 45.0 | 45.0 | 45.0 | 45.0 | 45.0 | 45.0 | 45.0 | 45.0 | 45.0 | 45.0 | 45.0 | 45.0 |
| Porogen/Monomer Ratio | 0.8182 | 0.8182 | 0.8182 | 0.8182 | 0.8182 | 0.8182 | 0.8182 | 0.8182 | 0.8182 | 0.8182 | 0.8182 | 0.8182 |
| Benzoyl Peroxide (BPO) | 1.03 | 1.03 | 1.03 | 1.03 | 1.03 | 1.03 | 1.03 | 1.03 | 1.03 | 1.03 | 1.03 | 1.03 |
| Wt. % | ||||||||||||
| Porogen Composition | ||||||||||||
| Isooctane, Wt. % | 98.915 | 98.915 | 98.915 | 98.915 | 98.915 | 98.915 | 98.915 | 98.915 | 98.915 | 98.915 | 98.915 | 98.915 |
| Toluene, Wt. % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inerts, Wt. % | 1.085 | 1.085 | 1.085 | 1.085 | 1.085 | 1.085 | 1.085 | 1.085 | 1.085 | 1.085 | 1.085 | 1.085 |
| Toluene plus Inerts, Wt. % | — | — | — | — | — | — | — | — | — | — | — | — |
| Isooctane/Toluene plus Inerts | — | — | — | — | — | — | — | — | — | — | — | — |
| Ratio | ||||||||||||
| Aqueous Phase | ||||||||||||
| Composition | ||||||||||||
| Sodium Carbonate, Wt. % | 0.300 | 0.100 | 0.500 | 0.500 | 0.500 | 0.500 | 0.500 | 0.500 | 0.500 | 0.500 | 0.500 | 0.500 |
| Sodium Nitrate, Wt. % | 0.300 | 0.100 | 0.300 | 0.300 | 0.300 | 0.300 | 0.300 | 0.300 | 0.300 | 0.300 | 0.300 | 0.300 |
| Poly(N-Vinylpyrrolidione) Wt. % | 0.010 | 0.010 | 0 | 0.05 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PVP K 30, 45-55 Kdaltons, | 0.010 | 0.010 | 0 | 0.05 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Wt. % | ||||||||||||
| PVP K 60, 400-500 Kdaltons, | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Wt. % | ||||||||||||
| Poly(Vinyl alcohol), Wt. % | 0.250 | 0.400 | 0 | 0 | 0 | 0 | 0.300 | 0.300 | 0.300 | 0.300 | 0.300 | 0.300 |
| Molecular Size, Kdaltons | 95 | 95 | — | — | — | — | 170 | 170 | 170 | 170 | 170 | 170 |
| Amount Hydrolyzed, % | 95 | 95 | — | — | — | — | 88 | 88 | 88 | 88 | 88 | 88 |
| Natrosol Plus, Wt. % | 0 | 0 | 0.500 | 0.300 | 0.300 | 0.300 | 0 | 0 | 0 | 0 | 0.05 | 0 |
| Aqueous/Organic Phase | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 |
| Volume Ratio | ||||||||||||
| Sample | Sample | Sample | ||||||||||
| ID | ID | ID | ||||||||||
| LDM | 02-082 | 02-083 | 02-086 | |||||||||
| Organic Phase | ||||||||||||
| Composition | ||||||||||||
| Monomer (DVB & EVB) Wt. % | 55.0 | 55.0 | 55.0 | |||||||||
| Porogen Wt. % | 45.0 | 45.0 | 45.0 | |||||||||
| Porogen/Monomer Ratio | 0.8182 | 0.8182 | 0.8182 | |||||||||
| Benzoyl Peroxide (BPO) | 1.03 | 1.03 | 1.03 | |||||||||
| Wt. % | ||||||||||||
| Porogen Composition | ||||||||||||
| Isooctane, Wt. % | 98.915 | 98.915 | 98.915 | |||||||||
| Toluene, Wt. % | 0 | 0 | 0 | |||||||||
| Inerts, Wt. % | 1.085 | 1.085 | 1.085 | |||||||||
| Toluene plus Inerts, Wt. % | — | — | — | |||||||||
| Isooctane/Toluene plus Inerts | — | — | — | |||||||||
| Ratio | ||||||||||||
| Aqueous Phase | ||||||||||||
| Composition | ||||||||||||
| Sodium Carbonate, Wt. % | 0.500 | 0.500 | 0.500 | |||||||||
| Sodium Nitrate, Wt. % | 0.300 | 0.300 | 0.300 | |||||||||
| Poly(N-Vinylpyrrolidione) Wt. % | 0 | 0 | 0 | |||||||||
| PVP K 30, 45-55 Kdaltons, | 0 | 0 | 0 | |||||||||
| Wt. % | ||||||||||||
| PVP K 60, 400-500 Kdaltons, | 0 | 0 | 0 | |||||||||
| Wt. % | ||||||||||||
| Poly(Vinyl alcohol), Wt. % | 0.300 | 0.300 | 0.300 | |||||||||
| Molecular Size, Kdaltons | 170 | 100 | 170 | |||||||||
| Amount Hydrolyzed, % | 88 | 85 | 88 | |||||||||
| Natrosol Plus, Wt. % | 0 | 0 | 0 | |||||||||
| Aqueous/Organic Phase | 1.0 | 1.0 | 1.0 | |||||||||
| Volume Ratio | ||||||||||||
| TABLE 7 | ||||||||||
| Experimental Programs: Responses | ||||||||||
| Sample ID | Sample ID | Sample ID | Sample ID | Sample ID | Sample ID | Sample ID | Sample ID | Sample ID | Sample ID | |
| LDM-02-001 | LDM-02-004 | LDM-02-006 | LDM-02-008 | LDM-02-010 | LDM-02-017 | LDM-02-025 | LDM-02-034 | LDM-02-036 | LDM-02-038 | |
| Surface Characteristics | ||||||||||
| SEM; description (smooth, | nodes, | nodes, | nodes, | nodes, | nodes, | no nodes, | no nodes, | no nodes, | no nodes, | nodes, |
| nodes present, open or closed pore | closed | closed | closed | closed | closed | open | open | open | open | closed |
| structure) | ||||||||||
| Internal Pore Structure | ||||||||||
| BET Surface Area, S | 563.5001 | 652.7807 | 615.7039 | 614.4325 | 661.4491 | 519.8904 | 539.9826 | 537.1961 | 558.5673 | 556.5736 |
| Porosity, Pwt in ml.g − 1 | 0.921032 | 1.536987 | 1.530853 | 1.724477 | 1.772158 | 1.240885 | 1.389936 | 1.906947 | 1.958844 | 1.875443 |
| Pore modes greater than 100 A | 150 | 250, | 200, | 450 | 500 | 250, 310, | 320, 450 | 380, 490 | 210, 280 | 210, 280, 380 |
| Diameter from desorption | 400 | 600 | 550 | 430, 550, 750 | 550, 750, | 750, 950 | 380, 500, 650 | 500, 650, 910 | ||
| Isotherm. List each | 1200, 1800 | 1200, 1700 | 1600 | |||||||
| Pore modes range in A greater than 100 A diameter, | 100-250 | 100-500 | 100-700 | 100-700 | 100-600 | 100-1900 | 100-1800 | 100-1600 | 100-1600 | 100-1600 |
| desorption Isotherm. | ||||||||||
| Particle Size Distribution | ||||||||||
| Unclassified, directly from | ||||||||||
| reactor | ||||||||||
| Cytonchrome C Sorption | ||||||||||
| Static Assessment 500 mg/Liter Conc. | ||||||||||
| Mg cyto c sorbed/g | 15.2 | 43.35 | 42.95 | 63.05 | 79.7 | 135.9 | 155.8 | 86.6 | 82.0 | 72.4 |
| dry polymer at 3 hr contact | ||||||||||
| % of cyto C removed from | 19.23 | 53.8 | 51.46 | 66.22 | 73.78 | 82.64 | 82.49 | 85.12 | 85.26 | 68.78 |
| solution at 3 hr contact | ||||||||||
| Serum Albumin Sorption | ||||||||||
| % removed from solution with | 6.0 | 4.1 | 5.1 | |||||||
| a concentration of 35,000 mg/l | ||||||||||
| of serum albumin | ||||||||||
| Mg BSA(or HSA) sorbed/g dry polymer | 1681.7 | 313.9 | 328.1 | |||||||
| at 3 hr contact | ||||||||||
| Coating Assessment | ||||||||||
| ESCA Measurements for Surface Components | ||||||||||
| Atom Fraction on surface | ||||||||||
| C | 0.8702 | 0.8722 | 0.8917 | 0.8881 | 0.8855 | 0.6476 | 0.6134 | 0.8981 | 0.8682 | 0.8901 |
| O | 0.0784 | 0.0758 | 0.0682 | 0.0729 | 0.086 | 0.0795 | 0.1178 | 0.0778 | 0.935 | 0.0771 |
| N | 0.0514 | 0.052 | 0.0401 | 0.039 | 0.0284 | 0.0281 | none | 0.0241 | 0.0383 | 0.0328 |
| detected | ||||||||||
| Sample ID | Sample ID | Sample ID | Sample ID | Sample ID | Sample ID | Sample ID | Sample ID | Sample ID | ||
| LDM-02-040 | LDM-02-044 | LDM-02-054 | LDM-02-055A | LDM-02-075 | LDM-02-079 | LDM-02-082 | LDM-02-083 | LDM-02-086 | ||
| Cytonchrome C Sorption | ||||||||||
| Static Assessment 500 mg/Liter Conc. | ||||||||||
| Mg cyto c sorbed/g | 57.6 | 61.7 | 73.9 | 57.8 | 61.1 | |||||
| dry polymer at 3 hr contact | ||||||||||
| % of cyto C removed from | 61.4 | 65.5 | 79.8 | 63.6 | 74.9 | |||||
| solution at 3 hr contact | ||||||||||
| Serum Albumin Sorption | ||||||||||
| % removed from solution with a concentration of 35,000 mg/l of | 3.1 | |||||||||
| serum albumin | ||||||||||
| Mg BSA(or HSA) sorbed/g dry polymer | 203.1 | |||||||||
| at 3 hr contact | ||||||||||
| Coating Assessment | ||||||||||
| ESCA Measurements of Surface Components | ||||||||||
| Atom Fraction on surface | ||||||||||
| C | 0.8586 | 0.8748 | 0.8238 | 0.7924 | ||||||
| O | 0.0982 | 0.0897 | 0.1745 | 0.2076 | ||||||
| N | 0.0432 | 0.0355 | none | none | ||||||
| detected | detected | |||||||||
| Surface Characteristics | ||||||||||
| SEM; description (smooth, nodes present, open or | nodes, | nodes, | nodes, | |||||||
| closed pore structure) | closed | closed | closed | |||||||
| Internal Pore Structure | ||||||||||
| BET Surface Area, S | 549.64 | 545.38 | 536.79 | 525.15 | 531.47 | 528.93 | ||||
| Porosity, Pwt in ml.g − 1 | 1.8356 | 1.642 | 1.6567 | 1.6957 | 1.5232 | 1.3708 | ||||
| Pore modes greater than 100 A | 300; 400; | 250; 310; | 200; 300; | 300; 400; | 200; 300; | 250; 300; | ||||
| Diameter from desorption | 500; 650; | 450; 620; | 400; 500; | 600; 750; | 420; 550; | 400; 500; 600; | ||||
| Isotherm. List each | 850 | 800; 1200 | 650; 920 | 900 | 750; 900; 1200 | 750; 900; 1300 | ||||
| Pore modes range in A greater than 100 A diameter, desorption | 300-980 | 200-1300 | 200-1700 | 150-1300 | 100-1300 | 100-1400 | ||||
| Isotherm. | ||||||||||
| Particle Size Distribution | ||||||||||
| Unclassified, directly from | ||||||||||
| reactor | ||||||||||
Numerous modifications and variations of the present invention are possible in light of the above teachings. It is therefore to be understood that within the scope of the attendant claims attached hereto, this invention may be practiced otherwise than as specifically disclosed herein.
| Patent | Priority | Assignee | Title |
| 7112620, | Oct 18 2002 | CYTOSORBENTS CORPORATION | Hemocompatible polymer systems & related methods |
| 7201962, | Oct 18 2002 | CYTOSORBENTS CORPORATION | Hemocompatible coated polymer and related one-step methods |
| 7629049, | Oct 18 2002 | CYTOSORBENTS CORPORATION | Hemocompatible polymer systems and related devices |
| 9604196, | Nov 20 2006 | CYTOSORBENTS CORPORATION | Size-selective hemocompatible polymer system |
| Patent | Priority | Assignee | Title |
| 3957741, | Jan 17 1974 | California Institute of Technology | Crosslinked, porous, polyacrylate beads |
| 4046720, | Jan 17 1974 | California Institute of Technology | Crosslinked, porous, polyacrylate beads |
| 4140652, | Jan 12 1977 | Method of preparing blood-compatible sorbents for recovering exo- and endogenic poisons | |
| 4171283, | Aug 04 1976 | Kuraray Co., Ltd. | Hemoperfusion adsorbents |
| 4232004, | Sep 21 1977 | American National Red Cross | Antibody-specific solid phase immunoadsorbent, preparation thereof, and antibody purification therewith |
| 4435524, | May 19 1980 | GEON COMPANY, THE | Process for preparing spherical and porous vinyl resin particles |
| 4634604, | Jun 23 1983 | Ceskoslovenska akademie ved | Method for producing a biocompatible layer on the surface of particles of porous synthetic sorbents |
| 5013585, | Jun 13 1989 | Shin-Etsu Chemical Co., Ltd. | Method for the preparation of surface-modified silica particles |
| 5064668, | Jun 30 1989 | NABISCO, INC , A NJ CORP | Process for separation of sterol compounds from fluid mixtures |
| 5169754, | Oct 31 1990 | COULTER INTERNATIONAL CORP | Biodegradable particle coatings having a protein covalently immobilized by means of a crosslinking agent and processes for making same |
| 5326738, | Sep 15 1989 | Stable, covalently-bonded supports for chemical separation apparatus made through a hydride intermediate | |
| 5547575, | Mar 06 1991 | Sartorius Stedim Biotech GmbH | Method for the surface modification of formed bodies and formed bodies produced thereby |
| 5563214, | Aug 09 1994 | Cognis Corporation | Aqueous compositions containing polymerizable surfactant compounds |
| 5589396, | Sep 11 1990 | Sandia Corporation | Coatings with controlled porosity and chemical properties |
| 5633316, | Apr 15 1991 | STOCKHAUSE GMBH; Stockhausen GmbH | Surface crosslinked and surfactant coated absorbent resin particles and method of preparation |
| 5639620, | Oct 31 1990 | COULTER INTERNATIONAL CORP | Polymeric particles having a biodegradable gelatin or aminodextran coating and process for making same |
| 5683800, | Oct 28 1994 | The Dow Chemical Company; DOW CHEMICAL COMPANY, THE | Surface-modified post-crosslinked adsorbents and a process for making the surface modified post-crosslinked adsorbents |
| 5773384, | Nov 25 1996 | BRODIE, STEFAN; BRODIE, DONALD | Sorbents for removing toxicants from blood or plasma, and method of producing the same |
| 5776706, | Oct 31 1990 | Coulter Corporation | Polymeric particles having a biodegradable gelatin or aminodextran coating and processes for making same |
| 5807636, | Nov 17 1995 | Advanced Surface Technology | Durable hydrophilic surface coatings |
| 5897953, | Oct 05 1993 | Asahi Kogaku Kogyo Kabushiki Kaisha | Granular polymer composite and production process thereof as well as diagnostic agent |
| 5904663, | Jul 30 1997 | BRODIE, STEFAN; BRODIE, DONALD | Method of removing beta-2 microglobulin from blood |
| 5922161, | Jun 30 1995 | Commonwealth Scientific and Industrial Research Organisation | Surface treatment of polymers |
| 5935845, | Oct 31 1989 | The United States of America as represented by theAdministrator, | Distributed pore chemistry in porous organic polymers |
| 5945457, | Oct 01 1997 | A V TOPCHIEV INSTITUTE OF PETROCHEMICAL SYNTHESIS, RUSSIAN ACADEMY OF SCIENCE | Process for preparing biologically compatible polymers and their use in medical devices |
| 6087300, | Feb 06 1998 | CYTOSORBENTS CORPORATION | Method of producing material for purification of physiological liquids of organism |
| 6103126, | Nov 24 1992 | SeBo GmbH | Process for the selective elimination of inorganic phosphate from liquids by means of absorbent materials modified with polynuclear metal oxyhydroxides |
| 6114466, | Feb 06 1998 | CYTOSORBENTS CORPORATION | Material for purification of physiological liquids of organism |
| 6127311, | Feb 06 1998 | CYTOSORBENTS CORPORATION | Method of producing material for purification of physiological liquids of organism |
| 6133393, | Feb 06 1998 | CYTOSORBENTS CORPORATION | Method of purification of physiological liquids of organism |
| 6136424, | Feb 06 1998 | CYTOSORBENTS CORPORATION | Method of and material for purification of physiological liquids of organism, and method of producing the material |
| 6153707, | Feb 06 1998 | CYTOSORBENTS CORPORATION | Method of producing material for purification of physiological liquids of organism |
| 6156851, | Feb 06 1998 | BRODIE, STEFAN; BRODIE, DONALD | Material for purification of physiological liquids of organism |
| 6159377, | Feb 06 1998 | CYTOSORBENTS CORPORATION | Method of purification of physiological liquids of organism |
| 6238795, | Jan 22 1999 | The Dow Chemical Company | Surface modified polymer beads |
| 6303702, | Feb 06 1998 | CYTOSORBENTS CORPORATION | Method of producing material for purification of physiological liquids of organism |
| 6325939, | Jan 22 1999 | The Dow Chemical Company | Surface modified polymer beads |
| 6338801, | Jan 22 1999 | The Dow Chemical Company | Surface modified polymer beads |
| 6387974, | Aug 11 2000 | Rohm and Haas Company | Polymeric adsorbents and method of preparation |
| 6408894, | Apr 25 2001 | CYTOSOBENTS CORPORATION | Method of producing devices for blood purification |
| 6416487, | Jul 30 1997 | CYTOSORBENTS CORPORATION | Method of removing beta-2 microglobulin from blood |
| 6419830, | Jan 22 1999 | The Dow Chemical Company | Surface modified polymer beads |
| 6423024, | Jan 22 1999 | The Dow Chemical Company | Device for removing toxins from blood or plasma |
| 6531523, | Oct 10 2000 | CYTOSOBENTS CORPORATION | Method of making biocompatible polymeric adsorbing material for purification of physiological fluids of organism |
| 20020037983, | |||
| 20020042487, | |||
| 20040076845, |
| Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
| Aug 20 2007 | ALBRIGHT, ROBERT L | MEDASORB TECHNOLOGIES, INC | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 019767 | 0444 | |
| Jun 06 2017 | MEDASORB TECHNOLOGIES, INC | CYTOSORBENTS CORPORATION | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 044386 | 0957 | |
| Jun 28 2024 | CYTOSORBENTS CORPORATION | AVENUE CAPITAL MANAGEMENT II, L P | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 067964 | 0382 |
| Date | Maintenance Fee Events |
| Oct 21 2008 | ASPN: Payor Number Assigned. |
| Oct 27 2008 | M2551: Payment of Maintenance Fee, 4th Yr, Small Entity. |
| Oct 26 2012 | M2552: Payment of Maintenance Fee, 8th Yr, Small Entity. |
| Oct 26 2016 | M2553: Payment of Maintenance Fee, 12th Yr, Small Entity. |
| Date | Maintenance Schedule |
| Apr 26 2008 | 4 years fee payment window open |
| Oct 26 2008 | 6 months grace period start (w surcharge) |
| Apr 26 2009 | patent expiry (for year 4) |
| Apr 26 2011 | 2 years to revive unintentionally abandoned end. (for year 4) |
| Apr 26 2012 | 8 years fee payment window open |
| Oct 26 2012 | 6 months grace period start (w surcharge) |
| Apr 26 2013 | patent expiry (for year 8) |
| Apr 26 2015 | 2 years to revive unintentionally abandoned end. (for year 8) |
| Apr 26 2016 | 12 years fee payment window open |
| Oct 26 2016 | 6 months grace period start (w surcharge) |
| Apr 26 2017 | patent expiry (for year 12) |
| Apr 26 2019 | 2 years to revive unintentionally abandoned end. (for year 12) |